Table 1. Characteristics of asthma patients with and without obstructive sleep apnoea (OSA).
| All patients (n = 55) | OSA (n = 27) | Non-OSA (n = 28) | |
|---|---|---|---|
| Age (years) | 47.8±1.7 [17–78] | 51.2±2.5 [24–78] | 44.6±2.2 [17–70] |
| Male (n/%) | 12/21.8% | 7/26.0% | 5/17.8% |
| BMI (kg/m2) | 28.4±0.8 [20–50.6] | 29.6±1.4 [20.6–50.6] | 27.2±0.8 [20–37.4] |
| BMI >30 (n/%) | 16/29% | 8/29.6% | 8/28.5% |
| Age at asthma onset (years) | 23.2±4.0 [1–70] | 28.4±4.0 [1–70] | 17.6±3.0 [1–45] * |
| Asthma control test | 10.3±0.8 [6–22] | 10.01 ± 0.9 [6–20] | 10.5 ± 1.0 [5–22] |
| Daily oral steroid use (n) | 13/23.6% | 7/26.0% | 6/21.4% |
| Inhaled steroid dose (μg/d) | 1902±41 [1600–2000] | 1927±33 [1600–2000] | 1878±74 [1600–2000] |
| Antileukotriene agent | 45/82% | 23/85% | 22/78.5% |
| Nasal steroid | 44/80% | 18/66.6% | 26/92.8%* |
| Antihistamine | 33/60% | 9/33% | 24/85%* |
| Atopy (n/%) | 29/52.7% | 7/26% | 22/78.5% * |
| Chronic rhinitis (n/%) | 44/80% | 18/66% | 26/93%* |
| Nasal polyposis (n/%) | 18/32.7% | 6/22% | 12/43% |
| GERD symptoms (n/%) | 40/72.7% | 21/78% | 19/68% |
| Depression (n/%)$ | 16/29% | 9/33% | 7/25% |
| Hypertension (n/%) | 15/27% | 11/41% | 4/14%* |
| Cerebrovascular disease (n/%) | 4/7% | 4/15% | 0/0%* |
| Diabetes (n/%) | 4/7% | 3/11% | 1/3.5% |
| Dyslipidaemia (n/%) | 3/5% | 1/4% | 2/7% |
| FEV1 (% predicted) | 65.2±2.3 [24–116] | 69.9±4.2 [24–118] | 67.4±4.5 [28–116] |
| FEV1/FVC (%) | 61±2.7 [27–92] | 62.1±2.2 [40–84] | 61.1±2.7 [27–92] |
| FEV1 reversibility (n/%)** | 21/38% | 9/33% | 12/43% |
Data are mean±SEM and range or no. (%).
* p<0.05 compared with OSA.
** Reversibility observed at the time of evaluation.
$ Proportion of patients receiving antidepressant drugs.